Compare GFR & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GFR | MGTX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 924.7M | 881.7M |
| IPO Year | 2023 | 2018 |
| Metric | GFR | MGTX |
|---|---|---|
| Price | $7.73 | $8.85 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $7.72 | ★ $27.75 |
| AVG Volume (30 Days) | ★ 1.6M | 610.0K |
| Earning Date | 11-09-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | N/A | ★ 0.68 |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $314.19 |
| Revenue Next Year | $142.30 | N/A |
| P/E Ratio | ★ $4.33 | $7.43 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $4.15 | $6.62 |
| 52 Week High | $7.81 | $15.35 |
| Indicator | GFR | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.18 | 39.22 |
| Support Level | $5.63 | $8.88 |
| Resistance Level | N/A | $10.08 |
| Average True Range (ATR) | 0.23 | 0.50 |
| MACD | 0.14 | 0.09 |
| Stochastic Oscillator | 96.46 | 29.03 |
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations. The company is actively developing its Hangingstone Facilities using SAGD, an enhanced oil recovery extraction method.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.